相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ERBB2-Low Breast Cancer-Is It a Fact or Fiction, and Do We Have the Right Assay?
Kimberly H. Allison et al.
JAMA ONCOLOGY (2022)
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Aileen Fernandez et al.
JAMA ONCOLOGY (2022)
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Aleix Prat et al.
EBIOMEDICINE (2022)
Prognostic and biologic significance of HER2-low expression in early breast cancer
P. Tarantino et al.
ANNALS OF ONCOLOGY (2022)
Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2,-3, and-7 studies of ribociclib plus endocrine therapy in patients with HR+/HER2-advanced breast cancer
Lisa Carey et al.
CANCER RESEARCH (2022)
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)- related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management
Sandra M. Swain et al.
CANCER TREATMENT REVIEWS (2022)
Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics.
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
Raz Mutai et al.
BREAST (2021)
Targeting HER2 heterogeneity in breast cancer
Erika Hamilton et al.
CANCER TREATMENT REVIEWS (2021)
Disitamab Vedotin: First Approval
Emma D. Deeks
DRUGS (2021)
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini et al.
NPJ BREAST CANCER (2021)
Characterization of low HER2 expressions in de-novo metastatic breast cancer
P. Tarantino et al.
ANNALS OF ONCOLOGY (2021)
HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysis
R. Sanchez Bayona et al.
ANNALS OF ONCOLOGY (2021)
Breast cancer
Sibylle Loibl et al.
LANCET (2021)
Evolution of HER2-low expression from primary to recurrent breast cancer
Federica Miglietta et al.
NPJ BREAST CANCER (2021)
The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer
Kelvin K. H. Bao et al.
JAMA NETWORK OPEN (2021)
Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2-Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2-Breast Cancer
Sven Rosswag et al.
CANCERS (2021)
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
Luciana de Moura Leite et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.
Jiayu Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.
Marietta Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Machine learning models to quantify HER2 for real-time tissue image analysis in prospective clinical trials.
Benjamin Glass et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Retrospective analysis of HER2-low in young breast cancer patients.
Abeid Mohamed Athman Omar et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)-Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Carsten Denkert et al.
LANCET ONCOLOGY (2021)
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Elisa Agostinetto et al.
CANCERS (2021)
Results of a Randomized Phase IIb Trial of Nelipepimut-S thorn Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
G. Travis Clifton et al.
CLINICAL CANCER RESEARCH (2020)
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+
Louis Fehrenbacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
Barbara Pistilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Gaia Griguolo et al.
CANCERS (2020)
HER2-Targeted Therapies in HER2-Low-Expressing Breast Cancer
Tim Johannes Adrianus Dekker
JOURNAL OF CLINICAL ONCOLOGY (2020)
ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers
Lillian Skidmore et al.
MOLECULAR CANCER THERAPEUTICS (2020)
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
Edmund Graziani et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Clinical Application of Multiple Reaction Monitoring-Mass Spectrometry to Human Epidermal Growth Factor Receptor 2 Measurements as a Potential Diagnostic Tool for Breast Cancer Therapy
Misol Do et al.
CLINICAL CHEMISTRY (2020)
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2020)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji et al.
LANCET ONCOLOGY (2019)
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
Arielle J. Medford et al.
NPJ PRECISION ONCOLOGY (2019)
Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
Claire H. Li et al.
BREAST CANCER RESEARCH (2019)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer
Morten Ragn Jakobsen et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer
Michel E. Vandenberghe et al.
SCIENTIFIC REPORTS (2017)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
Chris Twelves et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
HER2 expression identifies dynamic functional states within circulating breast cancer cells
Nicole Vincent Jordan et al.
NATURE (2016)
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial
G. Viale et al.
ANNALS OF ONCOLOGY (2014)
HER2 testing: Current status and future directions
Edith A. Perez et al.
CANCER TREATMENT REVIEWS (2014)
The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective
Shaloo Gupta et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2014)
Distinguishing Score 0 From Score 1+in HER2 Immunohistochemistry-Negative Breast Cancer Clinical and Pathobiological Relevance
Kathleen Lambein et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
Mario Giuliano et al.
BREAST CARE (2013)
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Phase II Study of Single Agent Trifunctional Antibody Ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 Low Expressing Hormone-Refractory Advanced Breast Cancer Patients (ABC)
F. Cardoso et al.
CANCER RESEARCH (2010)
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
Frederick L. Baehner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
